Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nirmatrelvir + ritonavir + dabigatran
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nirmatrelvir + ritonavir + dabigatran is a combination of two antiviral agents and an oral anticoagulant. Nirmatrelvir is a peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro, also known as 3CLpro or nsp5 protease), which blocks viral replication by preventing processing of viral polyproteins. Ritonavir, originally developed as an HIV protease inhibitor, acts here primarily as a pharmacokinetic enhancer by inhibiting CYP3A4 to boost plasma concentrations of nirmatrelvir. Dabigatran is a direct thrombin (Factor IIa) inhibitor that prevents thrombin-mediated activation in the coagulation cascade, thereby reducing blood clot formation. This combination may be encountered in patients with COVID-19 who are on chronic anticoagulation therapy and require antiviral treatment[6][5][8].
- Brand names
- Paxlovid (for nirmatrelvir + ritonavir)Pradaxa (for dabigatran)
- Other names
- nirmatrelvir + ritonavir + dabigatran
02
Targets
ABCB1 (P-glycoprotein)CYP3A4 (Cytochrome P450 3A4)F2 (Thrombin)Mpro (3C-like proteinase of SARS-CoV-2)
Beyond the preview
Go deeper on nirmatrelvir + ritonavir + dabigatran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nirmatrelvir + ritonavir + dabigatran.